Indian regulators have turned their attention to pay-for-delay agreements, making the nation the latest to scrutinize such agreements that have particular impact on the pharmaceutical industry.

According to reports, the Competition Commission of India is examining patent settlements made between foreign brand-name pharmaceutical companies and their generic counterparts in India. Reports …read more

Source: Global Competition Law Blogs